Mineralys Therapeutics (MLYS) Capital Expenditures (2024 - 2025)
Quarterly results put Capital Expenditures at $15000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $15000.0 (down 84.38% YoY), and the annual figure for FY2025 was $15000.0, down 84.38%.
Mineralys Therapeutics has reported Capital Expenditures over the past 2 years, most recently at $15000.0 for Q4 2025.
- Capital Expenditures reached $15000.0 in Q4 2025 per MLYS's latest filing, down from $37000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $59000.0 in Q1 2024 and bottomed at $15000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 230.60 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Mineralys Therapeutics | 2.50 Bn | 2.50 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Sep 30, 2024 | 37,000.00 |
| Sep 30, 2024 | 37,000.00 |
| Mar 31, 2024 | 59,000.00 |
| Mar 31, 2024 | 59,000.00 |